Clinical implications of the 2021 edition of the WHO classification of central nervous system tumours
C Horbinski, T Berger, RJ Packer, PY Wen - Nature Reviews Neurology, 2022 - nature.com
A new edition of the WHO classification of tumours of the CNS was published in 2021.
Although the previous edition of this classification was published just 5 years earlier, in …
Although the previous edition of this classification was published just 5 years earlier, in …
The 2021 WHO classification of tumors of the central nervous system: an update on pediatric lowgrade gliomas and glioneuronal tumors
TA Bale, MK Rosenblum - Brain Pathology, 2022 - Wiley Online Library
The 2021 5th edition of the WHO Classification of Tumors of the Central Nervous System
reflects the discovery of genetic alterations underlying many central nervous system (CNS) …
reflects the discovery of genetic alterations underlying many central nervous system (CNS) …
[HTML][HTML] Dabrafenib plus Trametinib in Pediatric Glioma with BRAF V600 Mutations
Background Detection of the BRAF V600E mutation in pediatric low-grade glioma has been
associated with a lower response to standard chemotherapy. In previous trials, dabrafenib …
associated with a lower response to standard chemotherapy. In previous trials, dabrafenib …
Integrated molecular and clinical analysis of 1,000 pediatric low-grade gliomas
Pediatric low-grade gliomas (pLGG) are frequently driven by genetic alterations in the RAS-
mitogen-activated protein kinase (RAS/MAPK) pathway yet show unexplained variability in …
mitogen-activated protein kinase (RAS/MAPK) pathway yet show unexplained variability in …
Pediatric low-grade glioma in the era of molecular diagnostics
Low grade gliomas are the most frequent brain tumors in children and encompass a
spectrum of histologic entities which are currently assigned World Health Organisation …
spectrum of histologic entities which are currently assigned World Health Organisation …
Glioma: molecular signature and crossroads with tumor microenvironment
L Barthel, M Hadamitzky, P Dammann… - Cancer and Metastasis …, 2022 - Springer
In patients with glioblastoma, the average survival time with current treatments is short,
mainly due to recurrences and resistance to therapy. This insufficient treatment success is, in …
mainly due to recurrences and resistance to therapy. This insufficient treatment success is, in …
[HTML][HTML] Glioma subclassifications and their clinical significance
R Chen, M Smith-Cohn, AL Cohen, H Colman - Neurotherapeutics, 2017 - Elsevier
The impact of targeted therapies in glioma has been modest. All the therapies that have
demonstrated a significant survival benefit for gliomas in Phase III trials, including radiation …
demonstrated a significant survival benefit for gliomas in Phase III trials, including radiation …
Advances in the molecular genetics of gliomas—implications for classification and therapy
G Reifenberger, HG Wirsching… - Nature reviews Clinical …, 2017 - nature.com
Genome-wide molecular-profiling studies have revealed the characteristic genetic
alterations and epigenetic profiles associated with different types of gliomas. These …
alterations and epigenetic profiles associated with different types of gliomas. These …
Childhood brain tumors: current management, biological insights, and future directions: JNSPG 75th Anniversary Invited Review Article
IF Pollack, S Agnihotri, A Broniscer - Journal of Neurosurgery: Pediatrics, 2019 - thejns.org
Brain tumors are the most common solid tumors in children, and, unfortunately, many
subtypes continue to have a suboptimal long-term outcome. During the last several years …
subtypes continue to have a suboptimal long-term outcome. During the last several years …
BRAF Inhibition in BRAFV600-Mutant Gliomas: Results From the VE-BASKET Study
Purpose BRAF V600 mutations are frequently found in several glioma subtypes, including
pleomorphic xanthoastrocytoma (PXA) and ganglioglioma and much less commonly in …
pleomorphic xanthoastrocytoma (PXA) and ganglioglioma and much less commonly in …